Top Qs
Timeline
Chat
Perspective
Valiloxybate
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
Valiloxybate (INN, USAN;[2] developmental code name XW-10172) is an extended-release prodrug of γ-hydroxybutyrate (GHB; oxybate) which is under development for the treatment of narcolepsy.[1][3][4][5][6] It is also being investigated for treatment of excessive daytime sleepiness (EDS) in people with Parkinson's disease.[7] The drug is taken orally once per night.[1][4][5][8][6]
Remove ads
Pharmacology
It is an amino acid (L-valine) ester prodrug of GHB,[6][2] which itself acts as a GABAB and GHB receptor agonist.[9][10] Relative to administration of GHB itself, valiloxybate showed a delayed time to peak levels and an extended duration of GHB exposure in humans.[6] It is said to maintain desired GHB levels for 6 to 7 hours.[11] This profile is compatible with once-nightly dosing,[6] in contrast to GHB itself which is typically administered twice per night due to its very short elimination half-life.[12][13][14] In addition, unlike sodium oxybate, valiloxybate contains no sodium or cation, and hence avoids excessive sodium intake.[6][15]
Remove ads
History
Valiloxybate is under development by XW labs or XWPharma.[1] As of September 2025, no recent development has been reported, but valiloxybate has reached phase 1 clinical trials for treatment of narcolepsy and phase 2 trials for treatment of sleeping problems in Parkinson's disease.[1][7]
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads